CD274 and breast cancer: Researchers Cortes Javier et al. used CPS as primary end point and found no benefit in OS (Cortes J, Lipatov O, Im S-A, et al. ESMO, Barcelona, Spain; Sept 27– Oct 1, 2019), while TILs predict OS benefit to single agent pembrolizumab in KN119, contrary to PD-L1 (Sherene Loi et al., San Antonio Breast Cancer Conference 2019).